Mitumomab is a monoclonal antibody that is primarily used in the context of cancer therapy. It is designed to target specific antigens present on the surface of tumor cells, facilitating the immune system's ability to recognize and destroy these cells. The substance is characterized by its specificity, which allows it to bind to particular proteins associated with certain types of cancer, enhancing the therapeutic efficacy while minimizing damage to healthy tissues. Mitumomab is often studied for its potential in treating various malignancies, and its mechanism of action typically involves antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). As a biopharmaceutical, it is produced through recombinant DNA technology, ensuring a high degree of purity and consistency. The development and application of Mitumomab reflect the broader trend in oncology towards targeted therapies that leverage the body's immune response, aiming for improved outcomes in cancer treatment. However, like all therapeutic agents, it may have associated side effects and requires careful clinical evaluation.

Mitumomab

216503-58-1: Mitumomab is a monoclonal antibody that is primarily used in the context of cancer therapy. It is designed to target specific antigens present on the surface of tumor cells, facilitating the immune system's ability to recognize and destroy these cells. The substance is characterized by its specificity, which allows it to bind to particular proteins associated with certain types of cancer, enhancing the therapeutic efficacy while minimizing damage to healthy tissues. Mitumomab is often studied for its potential in treating various malignancies, and its mechanism of action typically involves antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). As a biopharmaceutical, it is produced through recombinant DNA technology, ensuring a high degree of purity and consistency. The development and application of Mitumomab reflect the broader trend in oncology towards targeted therapies that leverage the body's immune response, aiming for improved outcomes in cancer treatment. However, like all therapeutic agents, it may have associated side effects and requires careful clinical evaluation.

Mitumomab, an anti-idiotypic mouse IgG2b monoclonal antibody, mimics the ganglioside GD3 and is utilized in researching small-cell lung carcinoma [1].

Anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3.

CAS 216503-58-1

Mitumomab

Mitumomab

Ref: TM-T81786

Mitumomab

Ref: 3D-CLA1105